Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, delivered an adjusted loss per share of 26 cents in second-quarter 2023, narrower than the year-ago loss and the Zacks Consensus Estimate of a loss of 34 cen
PacBio (PACB) Tops on Q2 Earnings, Raises FY23 Revenue View
Report
There was a problem reporting this post.
Block Member?
Please confirm you want to block this member.
You will no longer be able to:
See blocked member's posts
Mention this member in posts
Invite this member to nests
Message this member
Add this member as a connection
Please note:
This action will also remove this member from your connections and send a report to the site admin.
Please allow a few minutes for this process to complete.